This is a routine refinancing that extends debt maturity by 5 years and maintains the same $1.8B commitment size. No financial data or guidance was reported. The covenant package is standard and the step-up for qualifying acquisitions signals flexibility for dealmaking. Monitor for any material acquisition announcements that could utilize the accordion feature or trigger the higher leverage limits.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $55.76entry
- T+1 · 6mo ago −1.04%α −1.32% · $55.18
- T+5 · 6mo ago −1.42%α −1.12% · $54.97
- T+20 · 5mo ago +2.39%α +4.18% · $57.09
- T+60 · 3mo ago +9.99%α +8.81% · $61.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit agreement. The facility matures on May 22, 2031, and carries financial covenants including a maximum consolidated leverage ratio of 4.00x (stepping to 4.50x post-qualifying acquisition), a maximum portfolio cash flow ratio of 5.00x, and a minimum coverage ratio of 2.50x. This refinancing extends Royalty Pharma's debt maturity profile and maintains ample liquidity for acquisitions and working capital.
Key Financial Metrics
Key Facts
- Royalty Pharma entered a $1.8B unsecured revolving credit facility on May 22, 2026.
- The facility matures on May 22, 2031 (5-year term).
- The agreement refinanced and replaced the prior $1.8B facility from September 2021.
- Financial covenants include: max consolidated leverage ratio 4.00x (4.50x step-up for qualifying acquisitions), max portfolio cash flow ratio 5.00x (5.50x step-up), min coverage ratio 2.50x.
- Initial pricing is at Level 2 (BBB/BBB/Baa2) with an applicable margin of 1.125% over Term SOFR and an unused commitment fee of 0.10%.
- The facility includes an accordion feature allowing up to $900M in additional commitments.
- L/C sublimit is $100M.
- Proceeds can be used for working capital, acquisitions, and purchase of royalty assets.
Financial Impact
Refinancing of $1.8B revolving credit facility with a 5-year maturity, same size as prior facility. No new net debt created.
Risk Factors
- Leverage could increase if the company funds large acquisitions, though the step-up covenants provide buffer.
- Uncertainty around future interest rates could impact borrowing costs on drawn amounts.
- No financial performance data was provided in this filing to assess current credit metrics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245163 |
| Document: d131735d8k.htm | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index-headers.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163-index.html | 0001193125-26-245163 |
| Document: 0001193125-26-245163.txt | 0001193125-26-245163 |
Track record
23 reports on RPRX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers